Medication info
Sambica HCT Tablet 5/20/12.5 mg

Sambica HCT Tablet 5/20/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
White-orange round film-coated tablets
Packaging
30 tablets (10 tablets/Alu-Alu × 3)
Approval status
Active

MFDS item code 201902020 · Approved 2019.04.03 · Insurance code 642307610

Summary

Main use
Treatment of essential hypertension not controlled by combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy). However, if blood pressure is not adequately controlled with amlodipine and olmesartan medoxomil combination therapy, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/40mg or with this medicine at 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 10/40mg or with this medicine at 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/25mg or 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since experience with this medicine in elderly patients, particularly those aged 75 years and older, is very limited, monitor patients very carefully when administering this medicine.
Child dose
Safety and efficacy have not been established in pediatric patients under 18 years of age; therefore, administration of this medicine is not recommended.

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by combination therapy

  • Essential hypertension
View approved original text

Combination therapy using amlodipine and olmesartan medoxomil is used in cases where blood pressure is not sufficiently controlled among patients with essential hypertension. These drugs act by dilating blood vessels and lowering blood pressure, and combining the two medications allows for more effective blood pressure control. Proper management of blood pressure is very important to reduce the risk of cardiovascular diseases. This combination therapy helps to stably improve the patients' blood pressure and maintain their health.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy). However, if blood pressure is not adequately controlled with amlodipine and olmesartan medoxomil combination therapy, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/40mg or with this medicine at 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 10/40mg or with this medicine at 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/25mg or 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since experience with this medicine in elderly patients, particularly those aged 75 years and older, is very limited, monitor patients very carefully when administering this medicine.

Child dose

Safety and efficacy have not been established in pediatric patients under 18 years of age; therefore, administration of this medicine is not recommended.

Precautions

This drug may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, and therefore, should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to this drug or any of its components, pregnant or breastfeeding women, and patients with severe hypotension or heart, kidney, or liver diseases should not use this drug. Patients with reduced blood volume or poor kidney function, patients with liver disease, etc., should be particularly careful when using this drug, and blood pressure, kidney function, and electrolyte levels should be regularly monitored during treatment. This drug lowers blood pressure, and may cause symptoms of hypotension, as well as dizziness or drowsiness, so caution should be exercised when driving or operating dangerous machinery. This drug may interact with other medications, therefore, it is important to consult with a doctor or pharmacist when taking it alongside lithium, non-steroidal anti-inflammatory drugs (NSAIDs), or other antihypertensive agents. Long-term use of this drug may lead to electrolyte imbalances, so potassium, sodium, calcium levels, etc., should be periodically checked through blood tests. Women who are pregnant or planning to become pregnant should consult with healthcare professionals before taking this drug, and breastfeeding women should also avoid taking this drug. The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age, so its use is not recommended. In the case of overdose, symptoms such as hypotension and palpitations may occur, so immediate medical assistance should be sought. This drug should be stored in a tightly closed container to protect it from light and moisture and kept out of reach of children, and it is recommended not to transfer it to another container.

Side effects

  • Peripheral edema
  • headache
  • dizziness
  • upper respiratory tract infection
  • nasopharyngitis
  • urinary tract infection
  • sialadenitis
  • leukopenia
  • thrombocytopenia
  • bone marrow suppression
Show 159 more
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • aplastic anemia
  • anaphylactic reaction
  • drug hypersensitivity
  • hyperkalemia
  • hypokalemia
  • anorexia
  • diabetes
  • hypercalcemia
  • hyperglycemia
  • hypomagnesemia
  • hyponatremia
  • hypochloremia
  • hypertriglyceridemia
  • hypercholesterolemia
  • hyperuricemia
  • hypochloremic alkalosis
  • hyperamylasemia
  • confusion
  • depression
  • apathy
  • sensitivity to stimulation
  • anxiety
  • mood changes
  • sleep disturbances
  • orthostatic dizziness
  • syncope
  • taste disturbance
  • hypertonicity
  • sensory reduction
  • paresthesia
  • peripheral neuropathy
  • drowsiness
  • fainting
  • seizures
  • loss of appetite
  • tremor
  • visual disturbances
  • reduced tear production
  • worsening of myopia
  • jaundice
  • vertigo
  • tinnitus
  • palpitations
  • tachycardia
  • myocardial infarction
  • arrhythmia
  • angina
  • hypotension
  • flushing
  • orthostatic hypotension
  • vasculitis
  • thrombosis
  • embolism
  • cough
  • bronchitis
  • dyspnea
  • pharyngitis
  • rhinitis
  • acute interstitial pneumonia
  • respiratory distress syndrome
  • pulmonary edema
  • diarrhea
  • nausea
  • constipation
  • dry mouth
  • abdominal pain
  • change in bowel habits
  • abdominal distension
  • dyspepsia
  • gastritis
  • gastric discomfort
  • gastroenteritis
  • gingival hyperplasia
  • paralytic ileus
  • pancreatitis
  • vomiting
  • hepatitis
  • jaundice
  • acute cholecystitis
  • autoimmune hepatitis
  • alopecia
  • angioedema
  • allergic dermatitis
  • erythema multiforme
  • erythema
  • skin lupus erythematosus-like reaction
  • pustular rash
  • exfoliative dermatitis
  • hyperhidrosis
  • photosensitivity reaction
  • pruritus
  • purpura
  • Quincke's edema
  • rash
  • recurrence of skin lupus erythematosus
  • toxic skin necrosis
  • Stevens-Johnson syndrome
  • urticaria
  • muscle spasms
  • joint swelling
  • muscle weakness
  • ankle edema
  • arthralgia
  • arthritis
  • low back pain
  • paresis
  • myalgia
  • bone pain
  • frequent urination
  • acute renal failure
  • hematuria
  • urination disorders
  • nocturia
  • interstitial nephritis
  • renal failure
  • erectile dysfunction
  • gynecomastia
  • asthenia
  • fatigue
  • chest pain
  • fever
  • influenza-like symptoms
  • lethargy
  • ennui
  • edema
  • pain
  • facial edema
  • elevated serum creatinine
  • elevated serum urea
  • elevated serum uric acid
  • decreased serum potassium
  • elevated gamma-glutamyl transferase
  • elevated alanine aminotransferase
  • elevated aspartate aminotransferase
  • elevated liver enzymes
  • elevated serum creatine phosphokinase
  • weight loss
  • weight gain
  • rhabdomyolysis
  • chronic malabsorption syndrome
  • dizziness
  • benign prostatic hyperplasia
  • benign salivary gland neoplasm
  • cerebral infarction
  • renal failure
  • abdominal distension
  • facial flushing
  • epistaxis
  • prostatic hyperplasia
  • prostatitis
  • dysphagia
  • papular rash
  • renal cell dysplasia
  • acute hearing loss
  • lymphadenitis
  • acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to protect it from air and moisture and should be stored at room temperature between 1 to 30 degrees Celsius. By storing it this way, the drug's effectiveness can be maintained and deterioration prevented.

Appearance and packaging

Appearance

White-orange round film-coated tablets

Package unit

30 tablets (10 tablets/Alu-Alu × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.